Global Performance Evaluation of the AMS CONTINUUM™ Device
- To evaluate Device performance in providing mucosa to mucosa apposition to facilitate sustainable vesico-urethral anastomosis during a radical prostatectomy procedure.
- To assess clinical outcomes of the Device in facilitating the vesico-urethral anastomosis following a radical prostatectomy.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Global Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy|
- Successful Device Placement [ Time Frame: During Radical Prostatectomy ] [ Designated as safety issue: No ]Successful Device placement was defined as the establishment of a water-tight anastomosis immediately post-Device placement.
- Functionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-procedure in Subjects With Successful Device Placement [ Time Frame: 7-21 days post-Device placement ] [ Designated as safety issue: No ]
Device removal was first attempted at the 7-day window; if extravasation was noted, the subject returned for a second attempt at the 14-day window. If extravasation was noted at the first and second attempts, the subject could then return for a 3rd and final removal at the 21-day window.
The following defines the timeframe of each removal attempt:
- 7-day window (7-10 days post-implant)
- 14-day window (13-15 days post-implant)
- 21-day window (19-21 days post-implant)
- Intraoperative/Postoperative Parameters [ Time Frame: At Device placement ] [ Designated as safety issue: No ]
- Percentage of Subjects Demonstrating Functionally Adequate Anastomosis at the 1st and 2nd Device Removal Visits [ Time Frame: 7 and 14 days post-Device placement ] [ Designated as safety issue: No ]
- Incontinence Rate and I-QOL Score [ Time Frame: Baseline, 6-week, 6 and 12-month evaluations ] [ Designated as safety issue: No ]
- Bladder Neck Contracture (BNC) Rate [ Time Frame: Subjects that develop BNC between the scheduled follow-up visits at 6 weeks, 6 and 12 months post-device removal ] [ Designated as safety issue: No ]
|Study Start Date:||October 2007|
|Study Completion Date:||November 2010|
|Primary Completion Date:||November 2010 (Final data collection date for primary outcome measure)|
Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
Other Name: Anastomosis Device
Radical prostatectomy (RP) is the most utilized surgical treatment option for localized prostate cancer due to the multi-focal nature of the disease. RP is most suitable for otherwise healthy men whose cancer is limited to a small area. The RP procedure involves removing the prostate gland, seminal vesicles and nearby lymph nodes. One of the most technically challenging and critical aspects in all of these surgical approaches is reconstruction of the interrupted urinary tract by hand sewing the vesico-urethral anastomosis. This is where the bladder neck is sewn to the urethra after the prostate has been removed.
CONTINUUM™ (study Device) is to be used as part of the RP procedure by facilitating the approximation of the bladder neck and urethral stump. The Device brings together and holds the tissue in place until adequate natural healing of the vesico-urethral anastomosis occurs thereby minimizing extravasation. The Device also provides a conduit for drainage of urine from the bladder out the urethra during tissue healing.
The concept of the CONTINUUM™ device and the feasibility of its operation have been successfully tested in animal and human studies. Pilot clinical studies in the United States (G060095) found that the majority of subjects who received and were discharged with the Device demonstrated a water-tight vesico-urethral anastomosis at the first Device removal visit. Additionally, no unanticipated adverse device effects (UADEs) were reported. The focus of the proposed study is to further verify the performance of the Device in global research centers.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01083199
|University of Patras|
|Rio-Patras, Greece, 26500|
|Hospital University Gregorio Maranon|
|Madrid, Spain, 28007|
|Principal Investigator:||Evangelos Liatsikos, MD||University of Patras|
|Principal Investigator:||Carlos Hernandez, MD||Hospital University Gregorio Maranon|